BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
A.J. Scheen. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trialsDiabetes & Metabolism 2020; 46(3): 186 doi: 10.1016/j.diabet.2020.01.002
2
Björn Holzhauer, Mouna Akacha, Georgina Bermann. Choice of estimand and analysis methods in diabetes trials with rescue medicationPharmaceutical Statistics 2015; 14(6): 433 doi: 10.1002/pst.1705
3
Giuseppe Derosa, Pamela Maffioli. Dipeptidyl Peptidase-4 Inhibitors: 3 Years of ExperienceDiabetes Technology & Therapeutics 2012; 14(4): 350 doi: 10.1089/dia.2011.0204
4
Eleni Bekiari, Chrysoula Rizava, Eleni Athanasiadou, Konstantinos Papatheodorou, Aris Liakos, Thomas Karagiannis, Maria Mainou, Maria Rika, Panagiota Boura, Apostolos Tsapas. Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetesEndocrine 2016; 52(3): 458 doi: 10.1007/s12020-015-0841-1
5
Li-Nong Ji, Chang-Yu Pan, Ju-Ming Lu, Hong Li, Qiang Li, Qi-Fu Li, Yong-De Peng, Hao-Ming Tian, Chen Yao, Zhi-Gang Zhao, Ru-Ya Zhang, Xiang-Ling Wang, Lei Wang. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision studyCardiovascular Diabetology 2013; 12(1): 118 doi: 10.1186/1475-2840-12-118
6
Lingli Zhou, Xiaoling Cai, Yingying Luo, Fang Zhang, Linong Ji. Baseline Triglyceride Level Affected the Efficacy of Vildagliptin in Treating Type 2 Diabetes: A Post Hoc Analysis of the VISION StudyJournal of Diabetes Research 2019; 2019: 1 doi: 10.1155/2019/9347132
7
Sanjay Chatterjee, Sudip Chatterjee. Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: An observational study (印度2型糖尿病患者使用维格列汀与二甲双胍联合治疗对血糖的影响:一项观察性研究)Journal of Diabetes 2014; 6(3): 237 doi: 10.1111/1753-0407.12078
8
Elisa Guarino, Laura Nigi, Aurora Patti, Cecilia Fondelli, Francesco Dotta. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitusExpert Opinion on Pharmacotherapy 2012; 13(9): 1377 doi: 10.1517/14656566.2012.667078
9
Michel P. Hermans, Tuncay Delibasi, Ian Farmer, Leif Lohm, Pierre Maheux, PierMarco Piatti, Elmas Malvolti, Silke Jörgens, Bernard Charbonnel. Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT studyCurrent Medical Research and Opinion 2012; 28(10): 1635 doi: 10.1185/03007995.2012.735646
10
M.A. Banerji, D. Purkayastha, B.H. Francis. Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: A retrospective analysis of the GALIANT studyDiabetes Research and Clinical Practice 2010; 90(2): 182 doi: 10.1016/j.diabres.2010.06.022
11
B. Ahrén, J. E. Foley, E. Bosi. Clinical evidence and mechanistic basis for vildagliptin's action when added to metforminDiabetes, Obesity and Metabolism 2011; 13(3): 193 doi: 10.1111/j.1463-1326.2010.01321.x
12
Li Zang, Yin Han, Lixian Chen, Daqing Hu, Hui Jin, Nailong Yang, Xiaoyun Shi, Linlang Liang, Mingming Liu, Hong Fan, Quanmin Li, Yiming Mu. Comparison of the Effectiveness and Safety of Vildagliptin Add-On to Metformin Versus Other Oral Dual Antidiabetes Agents in Patients with Type 2 Diabetes: The China Prospective Diabetes StudyDiabetes Therapy 2019; 10(4): 1391 doi: 10.1007/s13300-019-0645-z
13
Grigorios Rombopoulos, Magdalini Hatzikou, Athanasios Athanasiadis, Moyses Elisaf. Treatment Compliance with Fixed-Dose Combination of Vildagliptin/Metformin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy: A 24-Week Observational StudyInternational Journal of Endocrinology 2015; 2015: 1 doi: 10.1155/2015/251485
14
G. McInnes, M. Evans, S. Del Prato, M. Stumvoll, A. Schweizer, V. Lukashevich, Q. Shao, W. Kothny. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patientsDiabetes, Obesity and Metabolism 2015; 17(11): 1085 doi: 10.1111/dom.12548
15
William I. Sivitz, Lawrence S. Phillips, Deborah J. Wexler, Stephen P. Fortmann, Anne W. Camp, Margaret Tiktin, Magalys Perez, Jacqueline Craig, Priscilla A. Hollander, Andrea Cherrington, Vanita R. Aroda, Meng Hee Tan, Jonathan Krakoff, Neda Rasouli, Nicole M. Butera, Naji Younes. Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body WeightDiabetes Care 2020; 43(5): 940 doi: 10.2337/dc19-1769
16
Abdulrahman S. Alanazi. Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitorsSaudi Pharmaceutical Journal 2015; 23(6): 603 doi: 10.1016/j.jsps.2013.12.018
17
L.-N. Ji, C.-Y. Pan, J.-M. Lu, H. Li, D.-L. Zhu, Q. Li, Q.-F. Li, Y.-D. Peng, H.-M. Tian, C. Yao, Z.-G. Zhao, L. Wang, B.-H. Wang. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION)Diabetes, Obesity and Metabolism 2016; 18(8): 775 doi: 10.1111/dom.12667
18
Juan P. Frias, Zachary Zimmer, Raymond L.H. Lam, Guillermo Amorin, Catherine Ntabadde, Carol Iredale, Edward A. O'Neill, Samuel S. Engel, Keith D. Kaufman, Hideo Makimura, Michael F. Crutchlow. Double‐blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT‐M studyDiabetes, Obesity and Metabolism 2019; 21(5): 1128 doi: 10.1111/dom.13626
19
Hidekatsu Yanai, Yoshinori Masui, Reo Yoshikawa, Junwa Kunimatsu, Hiroshi Kaneko. Dipeptidyl peptidase-4 inhibitor for steroid-induced diabetesWorld Journal of Diabetes 2010; 1(3): 99-100 doi: 10.4239/wjd.v1.i3.99
20
D. Wu, L. Li, C. Liu. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysisDiabetes, Obesity and Metabolism 2014; 16(1): 30 doi: 10.1111/dom.12174
21
Gillian M. Keating. Vildagliptin: A Review of Its Use in Type 2 Diabetes MellitusDrugs 2014; 74(5): 587 doi: 10.1007/s40265-014-0199-3